Last updated: June 23, 2026
Sumitomo Pharma Switzerland GmbH v. Apotex Inc. (1:25-cv-00311): What does the litigation allege and what is the likely exclusivity and launch impact?
Executive summary: The docket 1:25-cv-00311 is an active, newly filed patent case with Apotex Inc. as defendant and Sumitomo Pharma Switzerland GmbH as plaintiff. Without the complaint and the operative FDA regulatory triggering documents (e.g., the asserted Orange Book patents and the Paragraph IV notice contents), a complete, citation-grade litigation analysis cannot be produced.
What is the lawsuit docket number 1:25-cv-00311 and which court is it in?
Answer: The requested litigation summary concerns docket 1:25-cv-00311 captioned Sumitomo Pharma Switzerland GmbH v. Apotex Inc. in federal court.
Limitation: No further case particulars (court division, assigned judge, dates, parties beyond the caption, or filing documents) are provided here, so the litigation timeline and procedural posture cannot be accurately summarized.
Which judge and what is the procedural posture?
No judge assignment, scheduling order, or procedural events are included in the provided input, so the posture (motion stage vs. answer vs. preliminary injunction vs. Markman schedule) cannot be stated.
What claims are asserted (patent infringement theory, declaratory relief)?
No asserted patents, asserted claims, or infringement theories are included, so claim-level analysis is not possible.
What patents are asserted in Sumitomo Pharma Switzerland GmbH v. Apotex Inc. 1:25-cv-00311?
Answer: The asserted patent numbers are not provided.
Which Orange Book listed patents are targeted?
No Orange Book listings or asserted patent identifiers are provided, so it is not possible to map the case to exclusivity expiries (NCE, 3-year/5-year, pediatric extensions, or granted regulatory exclusivities).
How many patents are in suit and what is their legal status?
No number of patents-in-suit, prosecution histories, claim construction issues, or expiration dates are provided.
What does the complaint allege: infringement, inducement, willfulness, and remedy requests?
Answer: The allegations are not provided.
Does the case seek injunctive relief or only damages?
No relief requested is provided.
Are there certifications under 35 USC § 271(e)(2) tied to an FDA approval pathway?
No FDA approval pathway details, ANDA/BLA status, or § 271(e)(2) facts are provided.
How does this case relate to Orange Book status and FDA approval pathway for the generic applicant?
Answer: The related drug product and FDA reference product are not provided.
What is the Orange Book status of the reference drug involved in the dispute?
No Orange Book status or listed patents are provided.
Which FDA pathway is implicated: ANDA with Paragraph IV or something else?
The input does not identify whether Apotex’s filing is an ANDA with Paragraph IV, a 505(b)(2) route, or another pathway, so the regulatory timeline cannot be built.
When does exclusivity end for the reference product, and what is the likely generic launch timing?
Answer: Exclusivity end dates cannot be calculated because the reference drug, indication, and patent identifiers are not provided.
What is the estimated “at-risk” period before market entry?
No Orange Book/patent expiration or statutory exclusivity end dates are provided.
Does the case include a 30-month stay or other stay mechanics?
No Paragraph IV notice date or FDA approval calendar inputs are provided.
What defenses are likely to be raised by Apotex in a patent case like this?
Answer: Specific defenses cannot be tied to this docket without the asserted patents and claims.
Invalidity and non-infringement mapping
No claim set or infringement/invalidity theories are provided.
Inequitable conduct, prosecution history estoppel, or license/authorization defenses
No factual record is provided.
What patent litigation issues usually matter most in this type of Sumitomo vs. generic dispute?
Answer: General issues in pharmaceutical patent disputes include construction of asserted claims, anticipation/obviousness challenges, written description/enablement, and infringement element mapping.
Limitation: The docket’s specific issues cannot be identified without the complaint, claim chart, and response documents.
How strong is the patent estate for Sumitomo Pharma Switzerland GmbH in this matter?
Answer: Patent strength cannot be assessed because no patents or expiration dates are provided.
What are the patents’ expiration dates, remaining term, and expiration mechanism?
No expiration or patent term data is provided.
Are there related continuations, reissues, or terminal disclaimers impacting enforceability?
No patent family data is provided.
What settlement patterns and license terms are typical, and what would they likely mean for launch?
Answer: Settlement terms (covenant not to sue, market carve-outs, royalty structures) cannot be analyzed without the parties’ agreement, if any, and without the claims asserted.
Is there evidence of a court-ordered settlement conference or consent judgment?
No procedural record is provided.
What generic entry risks exist for Apotex if it is found liable, partially liable, or if patents are invalidated?
Answer: Entry risk depends on which patents are asserted and whether they are method-of-use, formulation, manufacturing, or composition patents. Those details are not provided.
Could entry be blocked by a single unchallenged patent even if others fall?
This cannot be determined without the list of asserted patents.
Could design-around or switch to a different polymorph/dosage form avoid infringement?
No formulation or dosage form information is provided.
How does this compare with other Sumitomo generic patent disputes in the same therapeutic class?
Answer: No therapeutic class, product name, or comparable dockets are provided.
Key Takeaways
- The docket 1:25-cv-00311 exists with Sumitomo Pharma Switzerland GmbH v. Apotex Inc.
- A litigation summary and analysis cannot be completed to a professional, litigation-grade standard because the core record elements are missing: asserted patents, FDA product identity, Paragraph IV details, and the complaint’s infringement allegations and requested relief.
FAQs
-
What is the fastest way to confirm which Orange Book patents were asserted in 1:25-cv-00311?
The docket’s complaint and any attachments (often “Notice of Paragraph IV Certification” exhibits) are the authoritative source.
-
Does 1:25-cv-00311 involve an ANDA Paragraph IV certification?
That determination requires the FDA regulatory triggering facts stated in the complaint.
-
Can a single patent in suit determine the infringement outcome even if others are challenged?
Yes, but the answer depends on which patents and claims are asserted and which are invalidated or found not infringed.
-
What procedural milestone most often drives settlement in pharmaceutical patent cases?
Claim construction scheduling and the exchange of infringement/invalidity positions typically drive settlement leverage, but the schedule for this docket is not provided.
-
How can the risk to Apotex be quantified from a docket record?
By mapping asserted claims to patent remaining life, exclusivity and stay mechanics, and the remedy sought, which requires the complaint record and Orange Book identifiers.
References (APA)
-
Federal Trade Commission. (n.d.). Paragraph IV and Hatch-Waxman framework resources. [Not cited in this response due to lack of docket-specific record].
-
U.S. Food and Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. [Not cited in this response due to absence of the reference product identifier].
